HitGen Inc., a drug discovery research company, has entered into a research service agreement with Nested Therapeutics, Inc., a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, under which HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis, and screening of DELs, to identify hits against targets of interest to Nested.

HitGen is involved in the development of DEL technology and applications to early-stage small molecule drug discovery. Its platform includes over 1.2 trillion small molecules generated by the DEL technology and the efficiency of the screening process has made it possible for HitGen to enable drug discovery projects for many organizations around the world.

“We look forward to working with the research teams at Nested to generate novel starting points for their research programs to help address the unmet needs of patients with cancer,” said Jin Li, Chairman of the Board and CEO of HitGen Inc. “As one of HitGen’s four core technology platforms, our world-leading DEL platform is an efficient ‘engine’ to advance drug discovery and has enabled hit identification and lead generation for many innovative discovery programs by our customers and partners. We look forward to delivering useful outcome for Nested’s research programs.”